Literature DB >> 22308025

Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis.

Eduardo Mascareno1, Josephine Galatioto, Inna Rozenberg, Louis Salciccioli, Haroon Kamran, Jason M Lazar, Fang Liu, Thierry Pedrazzini, M A Q Siddiqui.   

Abstract

It is well known that the renin-angiotensin system contributes to left ventricular hypertrophy and fibrosis, a major determinant of myocardial stiffness. TGF-β1 and renin-angiotensin system signaling alters the fibroblast phenotype by promoting its differentiation into morphologically distinct pathological myofibroblasts, which potentiates collagen synthesis and fibrosis and causes enhanced extracellular matrix deposition. However, the atrial natriuretic peptide, which is induced during left ventricular hypertrophy, plays an anti-fibrogenic and anti-hypertrophic role by blocking, among others, the TGF-β-induced nuclear localization of Smads. It is not clear how the hypertrophic and fibrotic responses are transcriptionally regulated. CLP-1, the mouse homolog of human hexamethylene bis-acetamide inducible-1 (HEXIM-1), regulates the pTEFb activity via direct association with pTEFb causing inhibition of the Cdk9-mediated serine 2 phosphorylation in the carboxyl-terminal domain of RNA polymerase II. It was recently reported that the serine kinase activity of Cdk9 not only targets RNA polymerase II but also the conserved serine residues of the polylinker region in Smad3, suggesting that CLP-1-mediated changes in pTEFb activity may trigger Cdk9-dependent Smad3 signaling that can modulate collagen expression and fibrosis. In this study, we evaluated the role of CLP-1 in vivo in induction of left ventricular hypertrophy in angiotensinogen-overexpressing transgenic mice harboring CLP-1 heterozygosity. We observed that introduction of CLP-1 haplodeficiency in the transgenic α-myosin heavy chain-angiotensinogen mice causes prominent changes in hypertrophic and fibrotic responses accompanied by augmentation of Smad3/Stat3 signaling. Together, our findings underscore the critical role of CLP-1 in remodeling of the genetic response during hypertrophy and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308025      PMCID: PMC3339995          DOI: 10.1074/jbc.M111.288944

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure.

Authors:  Andrea A Domenighetti; Qing Wang; Marcel Egger; Stephen M Richards; Thierry Pedrazzini; Lea M D Delbridge
Journal:  Hypertension       Date:  2005-07-05       Impact factor: 10.190

2.  Signal transduction and activator of transcription (STAT) protein-dependent activation of angiotensinogen promoter: a cellular signal for hypertrophy in cardiac muscle.

Authors:  E Mascareno; M Dhar; M A Siddiqui
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

3.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A.

Authors:  P M Oliver; J E Fox; R Kim; H A Rockman; H S Kim; R L Reddick; K N Pandey; S L Milgram; O Smithies; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

4.  Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase.

Authors:  James S Swaney; David M Roth; Erik R Olson; Jennifer E Naugle; J Gary Meszaros; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-29       Impact factor: 11.205

5.  Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system.

Authors:  L Mazzolai; J Nussberger; J F Aubert; D B Brunner; G Gabbiani; H R Brunner; T Pedrazzini
Journal:  Hypertension       Date:  1998-06       Impact factor: 10.190

Review 6.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

7.  Distinct components of Janus kinase/signal transducer and activator of transcription signaling pathway mediate the regulation of systemic and tissue localized renin-angiotensin system.

Authors:  Yueling Guo; Eduardo Mascareno; M A Q Siddiqui
Journal:  Mol Endocrinol       Date:  2004-01-15

8.  Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling.

Authors:  Veronica Franco; Yiu-Fai Chen; Suzanne Oparil; Ji An Feng; Dajun Wang; Fadi Hage; Gilbert Perry
Journal:  Hypertension       Date:  2004-09-27       Impact factor: 10.190

9.  Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse.

Authors:  Tatsuhiko Mori; Yiu-Fai Chen; Ji An Feng; Tetsuya Hayashi; Suzanne Oparil; Gilbert J Perry
Journal:  Cardiovasc Res       Date:  2004-03-01       Impact factor: 10.787

10.  Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure.

Authors:  Motoaki Sano; Sam C Wang; Manabu Shirai; Fernando Scaglia; Min Xie; Satoshi Sakai; Toru Tanaka; Prathit A Kulkarni; Philip M Barger; Keith A Youker; George E Taffet; Yasuo Hamamori; Lloyd H Michael; William J Craigen; Michael D Schneider
Journal:  EMBO J       Date:  2004-08-05       Impact factor: 11.598

View more
  13 in total

Review 1.  RNA polymerase II transcription elongation control.

Authors:  Jiannan Guo; David H Price
Journal:  Chem Rev       Date:  2013-08-06       Impact factor: 60.622

2.  The expression of marker for endometrial stem cell and fibrosis was increased in intrauterine adhesious.

Authors:  Jianguo Hu; Biao Zeng; Xingwei Jiang; Lina Hu; Ying Meng; Yi Zhu; Min Mao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Lead optimization of HMBA to develop potent HEXIM1 inducers.

Authors:  Bo Zhong; Rati Lama; Wannarasmi Ketchart; Monica M Montano; Bin Su
Journal:  Bioorg Med Chem Lett       Date:  2014-01-17       Impact factor: 2.823

4.  Autonomic boundary conditions for ventricular fibrillation and their implications for a novel defibrillation technique.

Authors:  Isaac Naggar; Sae Uchida; Haroon Kamran; Jason Lazar; Mark Stewart
Journal:  J Physiol Sci       Date:  2012-08-15       Impact factor: 2.781

5.  Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal.

Authors:  Manya Dhar-Mascareno; Susan N Ramirez; Inna Rozenberg; Yves Rouille; John G Kral; Eduardo J Mascareno
Journal:  Mol Endocrinol       Date:  2016-02-09

6.  Role of STAT3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking STAT3 serine 727 phosphorylation.

Authors:  Fouad A Zouein; Carlos Zgheib; Shereen Hamza; John W Fuseler; John E Hall; Andrea Soljancic; Arnaldo Lopez-Ruiz; Mazen Kurdi; George W Booz
Journal:  Hypertens Res       Date:  2013-01-31       Impact factor: 3.872

Review 7.  BET-ting on chromatin-based therapeutics for heart failure.

Authors:  Saptarsi M Haldar; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2014-05-14       Impact factor: 5.000

8.  Effects of endometrial stem cell transplantation combined with estrogen in the repair of endometrial injury.

Authors:  Xinrong Wang; Hongchu Bao; Xuemei Liu; Chengde Wang; Cuifang Hao
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

9.  Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease.

Authors:  Archita Venugopal Menon; Jing Liu; Hanting Phoebe Tsai; Lingxue Zeng; Seungjeong Yang; Aarti Asnani; Jonghan Kim
Journal:  Blood       Date:  2022-02-10       Impact factor: 25.476

10.  Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice.

Authors:  Noritada Yoshikawa; Noriaki Shimizu; Takako Maruyama; Motoaki Sano; Tomohiro Matsuhashi; Keiichi Fukuda; Masaharu Kataoka; Toru Satoh; Hidenori Ojima; Takashi Sawai; Chikao Morimoto; Akiko Kuribara; Osamu Hosono; Hirotoshi Tanaka
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.